Skip to main content

FDA in Flux

A Mintz newsletter tracking rapid changes in policy and agency actions that impact medical, life sciences, and consumer product investment decisions and development strategies.

Filter by:

Life Sciences Viewpoints Thumbnail

FDA in Flux — January 2026 Newsletter

January 22, 2026 | Article | By Joanne Hawana, Benjamin Zegarelli

The January 2026 edition of FDA in Flux highlights significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors.

Read more
Life Sciences Viewpoints Thumbnail

FDA in Flux — December 2025 Newsletter

December 16, 2025 | Article | By Joanne Hawana, Benjamin Zegarelli

The December 2025 edition of FDA in Flux highlights significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors.

Read more
Life Sciences Viewpoints Thumbnail

FDA in Flux — November 2025 Newsletter

November 19, 2025 | Article | By Joanne Hawana, Benjamin Zegarelli

The November 2025 edition of FDA in Flux highlights significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors.

Read more
Life Sciences Viewpoints Thumbnail

FDA in Flux – October 2025 Newsletter

October 16, 2025 | Article | By Joanne Hawana, Benjamin Zegarelli

The October 2025 edition of FDA in Flux highlights significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors.

Read more
Life Sciences Viewpoints Thumbnail

FDA in Flux — September 2025 Newsletter

September 17, 2025 | Article | By Joanne Hawana, Benjamin Zegarelli

The September 2025 edition of FDA in Flux highlights significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors.

Read more
Life Sciences Viewpoints Thumbnail

FDA in Flux — August 2025 Newsletter

August 14, 2025 | Article | By Joanne Hawana, Benjamin Zegarelli

The August 2025 edition of FDA in Flux highlights significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors. Responding to President Trump’s executive order on reducing regulatory burdens, FDA announced the PreCheck program, with the goal of accelerating onshoring of drug manufacturing. FDA, HHS, and USDA have issued a joint request for data and information to develop a uniform definition of ultra-processed foods (UPF). FDA held a public meeting on August 4 to start negotiation for reauthorizing the Medical Device User Fee Amendments (MDUFA), providing a look at what stakeholders hope to achieve in terms of FDA commitments and performance goals. In July, FDA announced that it is revoking 52 individual “obsolete and unnecessary” food product standard-of-identity (SOI) regulations.

Read more
Life Sciences Viewpoints Thumbnail

FDA in Flux — July 2025 Newsletter

July 9, 2025 | Article | By Joanne Hawana, Benjamin Zegarelli

The July 2025 edition of FDA in Flux highlights five significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors.

Read more
Life Sciences Viewpoints Thumbnail

FDA in Flux — June 2025 Newsletter

June 12, 2025 | Article | By Joanne Hawana, Benjamin Zegarelli

Welcome to FDA in Flux – A Mintz newsletter tracking rapid changes in policy and agency actions that impact medical, life sciences, and consumer product investment decisions and development strategies.

Read more
Sign up to receive email updates from Mintz.
Subscribe Now

Explore Other Viewpoints: